Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp WT (NQ: LEXXW )

0.7125 +0.0125 (+1.79%)
Streaming Delayed Price Updated: 12:31 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp WT

< Previous 1 2 3 4 5 6 7 Next >
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Via ACCESSWIRE
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Via ACCESSWIRE
Lexaria Welcomes Industry Veteran as New CEO
Via ACCESSWIRE
First Results from Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Updates Current GLP-1 Market
Via ACCESSWIRE
Lexaria Appoints Michael Shankman as Chief Financial Officer
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Releases Strategic Letter from the Outgoing CEO
Via ACCESSWIRE
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Via ACCESSWIRE
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Results from Lexaria's Molecular Characterization Study
Via ACCESSWIRE
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Via ACCESSWIRE
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
Via CannabisNewsWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Lexaria Preparing For Strategic Growth
Via ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Via ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.